Back

Temporal trends and clinical predictors of GLP-1 receptor agonist and SGLT2 inhibitor use after myocardial infarction among patients with type 2 diabetes

29 August 2026 (08:55 - 09:05)
Organised by: Logo
Congress Presentation Part of: Secondary prevention after myocardial infarction Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Gorav Batra

Uppsala University, Uppsala (Sweden)

5 More presentations in this session

Presentation thumbnail
The cardiovascular-kidney-liver-metabolic (CKLM) risk spectrum: synergistic mortality from liver fibrosis and cardiometabolic disease
Doctor S. Zuo (Xi'an, CN)
Abstract Slides
Presentation thumbnail
Impact of coronary computed tomography angiography image visualisation on low-density lipoprotein cholesterol reduction in non-obstructive coronary artery disease: a multicentre randomised trial
Doctor A. Kulasingam (Aarhus, DK)
Abstract Slides
Presentation thumbnail
Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis
Doctor S. Rajagopalan (Cleveland, US)
Abstract Slides
Presentation thumbnail
Attainment of secondary prevention goals after myocardial infarction in foreign-born versus native-born patients: nationwide data from SWEDEHEART
Doctor S. Zwackman (Linkoping, SE)
Abstract Slides
Presentation thumbnail
Cross-physiological and fitness-adjusted assessment of rate–pressure product for residual mortality risk stratification in acute coronary syndrome
Mr H. Cui (Harbin, CN)
Abstract Slides

Access the full session

Session thumbnail
Secondary prevention after myocardial infarction
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:55 CET
You may be interested in
thumbnail
Congress Presentation
Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease
27 August 2022
thumbnail
Congress Presentation
Time trends in risk factor control and use of secondary preventive medication among patients with myocardial infarction attending cardiac rehabilitation: data from the SWEDEHEART registry 2006-2017
30 August 2020
thumbnail
Congress Presentation
Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study
1 September 2025
thumbnail
Congress Presentation
Treatment with SGLT2 inhibitors in the early phase post acute myocardial infarction
15 March 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources